Moreover, TRIM22 inhibits endometrial cancer progression and improves prognosis by targeting the nucleotide binding oligomerization domain containing 2 (NOD2)/nuclear factor κB (NF-κB) signaling pathway (20). The gene discussed is NOD2; the disease is endometrial cancer.